|
TRIM23 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.63399999881287E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.42160000005109E-06 |
| Normal-vs-Stage2 |
7.768100E-04 |
| Normal-vs-Stage3 |
2.90530000002232E-06 |
| Normal-vs-Stage4 |
1.79810000000558E-06 |
| Stage1-vs-Stage2 |
8.969000E-01 |
| Stage1-vs-Stage3 |
4.773000E-01 |
| Stage1-vs-Stage4 |
1.476820E-01 |
| Stage2-vs-Stage3 |
7.238400E-01 |
| Stage2-vs-Stage4 |
2.994400E-01 |
| Stage3-vs-Stage4 |
3.973400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.93319999587072E-08 |
| Normal-vs-AfricanAmerican |
7.308300E-02 |
| Normal-vs-Asian |
5.187200E-04 |
| Caucasian-vs-AfricanAmerican |
1.279620E-01 |
| Caucasian-vs-Asian |
7.185800E-01 |
| AfricanAmerican-vs-Asian |
2.580600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.368700000004E-06 |
| Normal-vs-Female |
1.16620000001344E-06 |
| Male-vs-Female |
1.302820E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.06960000000067E-05 |
| Normal-vs-Age(41-60Yrs) |
6.99570000040062E-07 |
| Normal-vs-Age(61-80Yrs) |
9.07490000034983E-07 |
| Normal-vs-Age(81-100Yrs) |
4.818500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.953600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.372400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.082400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.320000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.055400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.643800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.164000E-02 |
| Classical-VS-Follicular |
3.529700E-02 |
| Classical-VS-Other |
3.275000E-01 |
| Classical-VS-Normal |
3.50319999999904E-05 |
| Tall-VS-Follicular |
6.274800E-01 |
| Tall-VS-Other |
9.407600E-01 |
| Tall-VS-Normal |
4.27130000002496E-06 |
| Follicular-VS-Other |
7.753200E-01 |
| Follicular-VS-Normal |
1.04580000004351E-06 |
| Other-VS-Normal |
2.666100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.38590000031691E-07 |
| Normal-vs-N1 |
2.760600E-04 |
| N0-vs-N1 |
9.344400E-01 |
|
|
